New Content  edit
Get The App!

A CME-Certified Breakfast Symposium

Advanced Management of Life-Threatening Bleeding in the Anticoagulated Patient

A CME-Certified Breakfast Symposium

Saturday, October 1, 2022
6:30am - 7:45am PT
San Francisco, California

Marriott Marquis San Francisco
780 Mission Street, San Francisco, CA
Golden Gate Ballroom A, Level B2
Breakfast will be provided

Online registration is now closed. Please come directly to the event. We look forward to seeing you there!

This symposium will be conducted during the 2022 ACEP Scientific Assembly. This program is not supported, endorsed, or accredited by ACEP’s Educational Meetings Committee.

Symposium Overview

This CME-certified symposium discusses the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It focuses on managing the anticoagulated patient with life-threatening intracranial bleeding, gastrointestinal bleeding, and post-traumatic bleeding in the Emergency Department, educating the audience through didactic, case-based presentations, and faculty panel discussion with audience Q & A.

Moderator

W. Brian Gibler, MD, FACEP, FACC, FAHA

President, EMCREG-International
Professor of Emergency Medicine
Department of Emergency Medicine
University of Cincinnati College of Medicine
Cincinnati, OH

Faculty

Brooks D. Cash, MD, AGAF, FACG, FASGE

Dan and Lillie Sterling Professor of Medicine
Chief, Gastroenterology, Hepatology, and Nutrition
UT Health Science Center at Houston
Houston, TX

Natalie Kreitzer, MD, MS

Associate Professor
Emergency Medicine and Neurocritical Care
University of Cincinnati
Cincinnati, OH

Babak Sarani, MD, FACS, FCCM

Professor of Surgery and Emergency Medicine
Director, Center for Trauma and Critical Care
George Washington University
Washington, DC

Full Accreditation and Program Information

Microlearning Agenda

6:30 am
Registration & Breakfast
6:45 am
Welcome & Introductions
6:50 am
Intracranial Hemorrhages and Anticoagulation Reversal in the ED - Dr. Natalie Kreitzer
  • Didactic Presentation
  • Case Review
7:05 am
Life-Threatening GI Bleeds and Anticoagulation Reversal in the ED - Dr. Brooks Cash
  • Didactic Presentation
  • Case Review
7:20 am
Life-Threatening Traumatic Bleeds and Anticoagulation Reversal in the ED - Dr. Babak Sarani
  • Didactic Presentation
  • Case Review
7:35 am
Faculty Panel Discussion - Audience Question & Answer
7:45 am
Adjourn

Target Audience

This program is designed to meet the educational needs of physicians involved in the management patients with life-threatening bleeds in the presence of an anticoagulant.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the risk factors for DOAC-related bleeding, as well as the appropriate diagnosis and monitoring of a life-threatening bleed, along with the associated need for treatment with a reversal strategy, particularly for ICHs
  • Identify the appropriate diagnostic approaches to upper and lower GI bleeding, describe the essential treatment and specialist interventions, and implement treatment
  • Review the clinical applications and recommendations associated with repletion and reversal agents for DOACs, based on an understanding of the mechanism of action, benefits, risks, dosing, monitoring, and management of these agents including anti-vitamin K therapies such as coumadin, or specific direct treatments such as Factor Xa or Factor IIa anticoagulants, and describe their application to clinical practice in the management of life-threatening bleeding

Accreditation Information

Joint Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati Office of Continuing Medical Education, EMCREG-International and TotalCME, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Fee Information : There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you.

Participants will receive an email after the event with a link to complete the evaluation form. Completion of the evaluation form will allow for credit to be processed and emailed to the participant

Supported by an educational grant from AstraZeneca
Jointly provided by the University of Cincinnati College of Medicine Office of Continuing Medical Education, EMCREG-International and TotalCME, Inc.